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Abstract
The liver has an intrinsic capacity to regenerate in response to
injury or surgical resection. Nevertheless, circumstances in which
hepatocytes are unresponsive to proliferative signals result in
impaired regeneration and hepatic failure. As the Hippo pathway
has a canonical role in the maintenance of liver size, we investi-
gated whether it could serve as a therapeutic target to support
regeneration. Using a standard two-thirds partial hepatectomy
(PH) model in young and aged mice, we demonstrate that the
Hippo pathway is modulated across the phases of liver regenera-
tion. The activity of the core kinases MST1 and LATS1 increased
during the early hypertrophic phase and returned to steady state
levels in the proliferative phase, coinciding with activation of YAP1
target genes and hepatocyte proliferation. Moreover, following PH
in aged mice, we demonstrate that Hippo signaling is anomalous
in non-regenerating livers. We provide pre-clinical evidence that
silencing the Hippo core kinases MST1 and MST2 with siRNA
provokes hepatocyte proliferation in quiescent livers and rescues
liver regeneration in aged mice following PH. Our data suggest
that targeting the Hippo core kinases MST1/2 has therapeutic
potential to improve regeneration in non-regenerative disorders.
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Introduction
Due to its intrinsic capacity to regenerate—the liver has been at the
forefront of clinical regenerative medicine and enables surgical
treatments for numerous hepatic disorders. Livers of patients with
cancer, parasitic infections or diseases that result in acute or chronic
liver failure can be resected or transplanted using living-related or
split-liver donor organs. In each circumstance, patient recovery
depends on the remnant liver mass to undergo compensatory
growth to return to its original weight and functional capacity.
Compensatory growth, or liver regeneration, following partial hepa-
tectomy is a rapid and efficient process in which the normally quies-
cent hepatocyte population re-enters cell cycle and proliferates until
the restoration of lost hepatic mass (Michalopoulos & DeFrances,
1997; Taub, 2004). However, there are cases in which regeneration
fails and this results in hepatic insufficiency and acute hepatic fail-
ure, known clinically as small for size syndrome (SFSS) (Troisi
et al, 2003; Zhong et al, 2006). Susceptible livers for SFSS include
those with cirrhosis or hepatosteatosis. Interestingly, ageing is also
an adverse factor for liver regeneration; several studies in mice and
humans demonstrated an age-dependent decline in the liver’s regen-
erative capacity following PH (Fry et al, 1984; Iakova et al, 2003;
Ledda-Columbano et al, 2004; Schmucker & Sanchez, 2011).
Although liver regeneration has been extensively investigated, many
regulatory pathways remain elusive and to date, there is no non-
invasive pharmacological means to support regeneration for clinical
use. In this study, we investigated a potential targeted treatment to
improve regeneration through inhibition of the Hippo pathway.
The Hippo pathway was originally identified in Drosophila by
screening for mutations resulting in organomegaly (Xu et al, 1995;
Harvey et al, 2003; Huang et al, 2005; Edgar, 2006; Camargo et al,
2007; Dong et al, 2007). The pathway is conserved in mammals and
regulates organ size and maintains tissue stem cells (Dong et al,
2007; Pan, 2007; Varelas et al, 2008; Alarcon et al, 2009; Lian et al,
2010; Yimlamai et al, 2014). The core pathway is composed of
serine–threonine kinases, mammalian Ste20-like protein kinase 1 and
2 [MST1/serine-threonine kinase 4 (STK4)] and [MST2/serine-threo-
nine kinase 3 (STK3)] and the large tumour suppressor kinase 1 and
2 (LATS1) and (LATS2), the scaffold protein Salvador (Sav1) and co-
factor Mob1. Its main downstream effectors are the transcription co-
activators Yes-associated protein (YAP) and transcriptional co-acti-
vator with PDZ-binding motif (TAZ) (Kanai et al, 2000; Huang et al,
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2005). When the canonical Hippo pathway is active, MST1/2 phos-
phorylates Sav1 facilitating its interaction and the phosphorylation of
LATS1/2 (Wu et al, 2003). Mob1 interacts directly with LATS
promoting LATS auto-phosphorylation. Active p-LATS1/2 phospho-
rylates YAP1 and TAZ, which facilitates their binding to 14-3-3
restricting them to the cytosolic fraction (Basu et al, 2003). Of note,
it has been proposed that in the liver YAP1 phosphorylation is not
solely dependent on p-LATS1/2 and can involve other intermediate
kinases downstream of MST1/2 (Zhou et al, 2009). When the Hippo
pathway is inactivated, YAP and TAZ are maintained in the nucleus
and bind with transcription factors such as p73, PAX3, PPARc,
RUNXs, SMAD, TBX5, PEBP2a, ErbB4 and their primary binding
partners, TEAD proteins (Yagi et al, 1999; Strano et al, 2001;
Vassilev et al, 2001; Basu et al, 2003; Komuro et al, 2003; Hong
et al, 2005; Murakami et al, 2006; Zhao et al, 2008a,b; Alarcon et al,
2009). Genes regulated by YAP activation are those that are involved
in cell proliferation and tissue growth, among which are ctgf, cyr61,
Birc5, Ccnb1, Foxm1 and Areg (Dong et al, 2007; Zhao et al, 2008b;
Zhang et al, 2009; Xin et al, 2011; Mizuno et al, 2012).
In transgenic models, the hepatic specific deletion of the Hippo
kinases, MST1/2, provokes hepatocyte proliferation and liver over-
growth (Zhou et al, 2009; Lu et al, 2010; Song et al, 2010) and a
similar outcome is obtained with liver-specific YAP1 overexpression
(Camargo et al, 2007; Dong et al, 2007). Here, we further investi-
gated whether proteins in the Hippo pathway are regulated by
regenerative signals following PH and play a physiological role in
the control of liver size. We describe that the expression and func-
tion of proteins in the Hippo pathway are differentially regulated in
young compared to aged livers following partial hepatectomy and
support that targeting its core kinases MST1/2 with siRNA is a
potential therapeutic intervention to improve the regenerative
capacity of resected livers.
Results
Regulation of Hippo and YAP1 during liver regeneration
Partial hepatectomy (PH) in rodents is a well-established, robust
model to study the complex processes involved in liver regeneration
(Higgins & Anderson, 1931). We questioned how the Hippo
pathway is regulated during liver regeneration by assessing the
expression and activation of the core kinases MST and LATS as well
as their effector protein YAP1 in C57Bl/6J mice following PH. Ki67
immunostaining was used to identify hepatocytes re-entering cell
cycle. Less than 2% of hepatocytes were Ki67 positive during the
hypertrophic phase (0–24 h post-PH) of liver regeneration (Miyaoka
et al, 2012), whereas up to 75% of hepatocytes became positive
during the proliferative phase (24–48 h post-PH) with peak Ki67
expression around 40 h (Fig 1A). Interestingly, we observed an
increase of the active, phosphorylated form of MST and LATS
(p-MST1/2 and p-LATS1) 6 and 24 h post-PH, which coincides with
the non-proliferative, hypertrophic phase of the liver following PH
(Fig 1B). As the liver advanced into the proliferative phase (24–48 h
post-PH), levels of p-MST1/2 and p-LATS1 decreased to steady state
levels. No significant changes in MST1 protein were detected post-
PH and no conclusion could be drawn on MST2 due to the high
background of the antibody (Appendix Fig S1A and B). Total LATS1
protein (150 kDa) steadily increased 24–48 h post-PH (Fig 1B and
Appendix Fig S1A) supporting its role in a YAP-induced feedback
mechanism regulation the Hippo pathway (Moroishi et al, 2015).
The antibody used to detect active MST recognizes both p-MST1
and p-MST2 at Thr183 and Thr180, respectively, and detected the
cleaved protein as a 34 and 27 kDa fragment (Praskova et al, 2004)
(Fig 1B). The band identified as p-LATS1 (Ser909) migrated at
approximately 150 kDa which was confirmed in a siRNA knock-
down experiment (Appendix Fig S2).
There was no significant transcriptional change in Mst1, Mst2 or
Lats1mRNA at 6, 24 or 48 h post-PH (Appendix Fig S3A). Activation
of the Hippo effector protein YAP1 was evident 48 h post-PH by its
increased expression in nuclear-enriched proteins isolated from liver
tissue (Fig 1C) and by its positive nuclear staining in hepatocytes
(Fig 1D). To provide further evidence that the parenchymal cells are
in part responsible for the increase of YAP protein following PH, we
demonstrated that YAP and TAZ are both detectable in isolated
cultures of hepatocytes and cholangiocytes (Fig EV1). In addition,
there is an increase of YAP expression in hepatocytes isolated from
regenerating livers 48 h after surgery compared to sham-operated
controls (Fig 1E). YAP activation was further confirmed by an up-
regulation of its target genes, Birc5 (68-fold), Foxm1B (80-fold) and
the mitotic cyclin, Ccnb1 (27-fold) 48 h post-PH (Fig 1F). There was
no significant change of the YAP target gene Ctgf (Appendix Fig S3B)
Figure 1. Regulation of the Hippo pathway and YAP during liver regeneration.
A Representative photomicrographs of mouse liver sections following a two-thirds PH of Ki67-positive hepatocytes (brown) visualized by IHC. Images are representative
of three independent animals per time point. Scale bars, 10 lm.
B Western blot detection of p-MST1, MST1, p-LATS1, LATS1 from proteins isolated from homogenized liver tissue at several time points. TBP was used as a loading
control. Results of a single experiment with n = 3 animals per group. Each band is from an independent animal. Protein levels were normalized to TBP and mean
value of the ratio of p-MST to total MST and p-LATS to total LATS is plotted.
C Nuclear-enriched protein fractions obtained from sham-operated livers and liver 48 h post-PH were analysed by Western blot for YAP expression. Sp1 was used as a
loading control. Image is representative of a single experiment with n = 3 animals per group.
D Photomicrograph of YAP1 expression in sham and regenerating liver 48 h post-PH visualized by immunofluorescence. Images are representative of three independent
animals per condition.
E Livers from sham and 48 h following PH were digested to isolate the hepatocyte population. Protein extracts were analysed by Western blot for YAP and TAZ
expression. b-actin was used as a loading control. Results of a single experiment with n = 2 animals per group. Each band is representative of an independent animal.
F RT–PCR analysis of RNA isolated from mouse liver for Birc5, Foxm1B and Ccnb1. Data are presented as log2 fold change and were calculated using non-operated
mouse liver tissue as a control. Unpaired, two-tailed Student’s t-test was used to determine the significance between the log2 values of livers 6, 24 and 48 h post-PH
compared to the sham-operated controls. Log2 values are plotted on a linear scale as mean  SD.
Source data are available online for this figure.
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or of Yap1 itself, whereas there was significant modulation of Taz
mRNA expression post-PH (Appendix Fig S3C). These data provide
evidence that the Hippo kinases are regulated during the events
following PH and YAP is active in regenerating livers.
Hepatocyte proliferation, Hippo signaling and YAP1 activation
are impaired in aged mice
We next assessed for age-related differences in the regulation of
Hippo pathway proteins by performing a 60% PH in aged
(> 12 months old) and young (6–8 week) mice. A fixed end time
point of 40 h was set in order to analyse liver tissue at the peak of
proliferation (Wang et al, 2001). Compared to 100% (6/6) of the
young mice, only 66% (6/9) of aged mice survived up to 40 h
within the parameters defined by our ethical score sheet. The non-
surviving aged mice recovered from surgery, but were severely
strained 24 h post-PH and required euthanization. The livers of
euthanized mice were determined to be not regenerating and were
excluded from further analysis. The proliferation index (p.i.) of the
remaining six aged and six young animals was calculated by the
ratio of Ki67-positive hepatocytes to total number of hepatocytes
and a p.i. of < 10% was used as a cut-off to classify the livers as ()
non-regenerating, while a p.i. of 10 or greater signified (+) regenera-
tion (Fig 2). The livers of all young mice 6/6 were regenerating
(p.i. = 75  10; Fig 2A) vs. only 2/9 of the aged livers (p.i. = 37.5
and 30.7; Fig 2B). The p.i. of the remaining four aged mice scored
< 10 (p.i. = 4.2  2.4; Fig 2C) and therefore was classified as non-
regenerating (Fig 2B). Histologically, all regenerating livers showed
discreet architectural changes, and young livers had slight microvas-
cular steatosis (Fig 2A), whereas aged regenerating livers had
marked steatosis (Fig 2B). Aged non-regenerating livers had signs of
foamy degeneration of the hepatocytes and virtually no hepatic
steatosis (Fig 2C).
Compared to young livers, aged livers had higher steady state
levels of pMST that remained elevated during regeneration (Fig 3A).
Steady state level of pLATS was also higher in aged animals and was
not modulated following PH (Appendix Fig S4). Total MST1 protein
decreased 40 h post-PH in young livers, but remained elevated in
aged mice. No difference was observed in levels of p-YAP between
young and aged animals. However, total YAP protein increased in
young animals following PH, whereas in aged animals there was a
higher steady state level that was not altered following PH (Fig 3A).
This observation was unique to YAP as TAZ expression increased in
a similar manner in both young and aged animals (Fig 3A). More-
over, there was no increase of YAP1 targets Foxm1B, Birc5, Ccnb1 or
other regulators of cell cycle such as, Ccna2 and Ccnd1 and a
tendency of higher Cdkn1A levels in non-regenerating aged animals
(Fig 3B). Taken together, these data support that there are age-
related defects in liver regeneration following PH and regulation of
the Hippo pathway is anomalous in non-regenerating aged livers.
Inhibition of MST1/2 with RNAi provokes hepatocyte
proliferation in vivo
Bringing together our observations presented above with data that
has shown MST1/2 are constitutively activated in a quiescent liver
(Zhou et al, 2009; Lu et al, 2010; Song et al, 2010), we chose to
inhibit MST1/2 by RNAi as a potential means to improve the liver’s
regenerative potential. Both MST1 and MST2 were targeted due to
their reported redundancy and overlapping function (Zhou et al,
2009; Lu et al, 2010). We screened and selected siRNA sequences
based on their ability to inhibit MST1 and MST2 expression in a
mouse liver cell line (Appendix Fig S5). For in vivo delivery, siRNAs
were encapsulated with liposomes and delivered by femoral vein
(i.v.) injection. In control experiments, we confirmed that the liver
and more specifically hepatocytes were targeted with lipid-encapsu-
lated siRNA by knocking down factor VII (FVII), a coagulation
protein synthesized specifically by hepatocytes. Venous injection of
lipid-encapsulated siRNA targeting FVII achieved an 80% reduction
of FVII mRNA in the liver and 90% reduction of circulating FVII
protein (Fig EV2).
In young mice, knockdown of MST1/2 with siRNA (siMST) effec-
tively reduced hepatic expression of Mst1 & Mst2 to 15 and 45%,
respectively, within 24 h after i.v. injection. The efficiency of the
knockdown declined over time but still partially remained 6 days after
injection (Fig 4A). Concordant with the loss of Mst1 mRNA, MST1
protein was depleted and lower levels of p-LATS1 were detected over
time (Fig 4B). In siMST livers, there was an increase of YAP1 and a
decrease of p-YAP1 in nuclear-enriched protein extracts 3 days after
injection (Fig 4C). The amount of nuclear proteins was normalized
with histone H3, which remained constant; however, its phosphory-
lated form (p-H3), a marker of mitosis, was increased in siMST-
injected livers (Fig 4C). There was a significant up-regulation of YAP1
target genes, Birc5 (2.8  0.2-fold), Foxm1B (5.3  0.3-fold) and
Ccnb1 (6.8  0.6-fold) at day 3 and Foxm1B (5.3  0.3-fold) and
Ccnb1 (6.8  0.6-fold) at day 6 (Fig 4D). The proliferation marker,
Ki67, was positive in the hepatocytes of the KD tissue, whereas the
biliary epithelial cells/bile ducts were negative, favouring a hepato-
cytic over ductal response (Fig 4E). The percentage of proliferating
cells was calculated by the number of Ki67-positive cells relative to
the total number of hepatocytes measured by nuclear size and HNF4-a
staining. siMST provoked a hepatocyte p.i. of 5.7  1.2 at day 3 and
6.9  1.5 at day 6 post-injection, whereas the p.i. of the scrambled
controls (siScr) was 1.1  0.8 (Fig 4E). We observed no increase of
liver-to-body weight ratio up to day 6 post-injection.
For a broader view on the effect of siRNA targeting MST1/2, we
used a gene expression microarray to compare the transcriptome of
livers treated with siMST with siScr and untreated control livers.
Few individual genes were significantly regulated between the
siMST and siScr groups; however, a gene set enrichment analysis
(GSEA) performed with the algorithm SetRank revealed several
affected pathways (Appendix Fig S6). The first group of genes had
known antiviral activity such as the 20–50 oligoadenylate synthetases
Oas2, Oas1a, Oasl1 and Oas1g and several MHC II genes such
H2-D1, H2-K1, H2-Q4 and H2-Q7 are related to interferon gamma
signaling. They were up-regulated when comparing the siMST livers
to both the siScr and untreated livers. Although this specific antivi-
ral response is not observed when comparing the siScr group to
untreated livers, it is still likely to constitute a reaction of the liver
cells to treatment with dsRNA, as we observe a different antiviral
response in the siScr livers (Appendix Fig S7A). The second group
related to cell cycle, more specifically with mitotic prophase. Livers
treated with siMST showed an up-regulation of several elements of
the kinetochore complex such as Kif2c, Nuf2 and Ndc80, along with
key cell cycle activators such as Cdk1 and Ccnb2 (Appendix Fig
S7B). The third group consists of gene sets related to the
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extracellular matrix (EM) such as the collagen genes Col1a1, Col1a2
and Col3a1, the laminin genes Lamb1, Lamb2 and Lamc1, fibulin 5
(Fbln5), fibrin 1 (Fbn1), heparan sulphate proteoglycan 2 (Hpgn2)
and lumican (Lum) (Appendix Fig S7C). The detection of gene sets
involved in cell proliferation and formation of matrix suggests that
transient inhibition of MST1/2 is permissive for organ growth.
Finally, analysis of the serum from control or siMST-injected
animals revealed no increase of alanine transaminase (ALT) or
aspartate transaminase (AST), suggesting that liver damage did not
account for the increased hepatic proliferation (Appendix Fig S8A).
In addition, there was no significant decrease of Mst1 or Mst2
mRNA expression in the lung and spleen indicating low, remote off-
target effects (Appendix Fig S8B).
Inhibition of MST1/2 improves liver regeneration in aged mice
We next tested the hypothesis that inhibition of MST1/2 could
rescue an age-related defect in liver regeneration. Aged mice were
injected with either siRNA targeting MST1/2 (siMST) or a scrambled
control (siScr) and 24 h after injection a 70% PH was performed.
The resected liver tissue was used to determine the efficiency of the
KD and siMST1/2 effectively knocked down hepatic expression of
Mst1 & Mst2 to 18 and 55%, respectively (Fig EV3). Forty hours
post-PH, there was a 0% (0/9) survival rate of the aged mice
injected with siScr, whereas there was 66% (6/9) survival of aged
mice injected with siMST (Fig 5A). The livers of siMST animals
scored with a mean p.i. of 36.17  11.18 (Fig 5B). Ki67-positive
cells were observed in the hepatocytic compartment of the livers
only; there were no signs of ductal reactions or oval cell expansion
as determined by H&E stain, CK-19 expression and Ki67 (Fig 5C).
As an additional sign of regeneration, Birc5, Foxm1B and Ccnb1
were significantly up-regulated 40 h post-PH in the aged siMST-
treated livers (Fig 5D). When comparing the regeneration of livers
treated with siMST to the non-treated aged controls, knockdown of
MST1/2 significantly increased the p.i. (aged: 14.2  15.7 vs.
siMST: 36.2  11.2; Fig 5E) and increased the liver-to-body weight
ratio (Fig 5F) demonstrating an overall advantage of targeting MST
in aged animals. To verify that cellular hypertrophy was not the
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Figure 2. Hepatocyte proliferation is impaired in aged mice.
A–C Representative photomicrograph of young (6–8 weeks) and aged (> 12 months) livers 40 h post-PH stained with Ki67 and visualized by IHC and H&E for histology.
Sections were scanned using 3DHistech Pannoramic MIDI Scanner and Ki67-positive cells were quantitated with Quant Center 2.0 software. A proliferation index
(p.i.) was calculated based on the number of Ki67-positive hepatocytes to total hepatocytes and livers were classified as (+) regenerating, p.i. > 10% or () non-
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D Number of young (6–8 weeks) and aged (> 12 months) mice with () non-regenerating or (+) regenerating livers based on p.i., 40 h post-PH. Animals deemed non-
surviving for ethical reasons were euthanized 24 h post-PH. Representative results from a single experiment with n = 9 aged and n = 6 young animals per group.
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cause of the increased liver-to-body weight ratio, the geometric
diameter of the hepatocytes was measured (Appendix Fig S9).
There was an increase of hepatocyte size in regenerating livers of
both young and aged animals. However, no significant change in
the size of regenerating hepatocytes was found in aged compared
to aged + siMST-treated animals (Fig 5G). This suggests that cellu-
lar hypertrophy is not the cause of the increased liver-to-body
weight ratio in the aged + siMST-treated animals, but rather an
increase of hepatocyte size and number. And finally, serum ALT,
AST and alkaline phosphatase (ALP) levels were elevated following
PH, indicating liver cell injury in aged animals; however, there
were no significant differences in regenerating aged mice treated or
not treated with siMST (Appendix Fig S10). Taken together, using
an aged mouse model, we demonstrate the clinical applicability of
targeting MST1/2 to improve the liver’s regenerative capacity.
Discussion
Our data demonstrate that the liver’s physiological growth response
following PH involves MST1 and LATS protein modification and
YAP1 activation, which is demonstrated by its nuclear localization
and transcriptional activation of target genes. YAP1 involvement in
liver regeneration is in agreement with others (Wu et al, 2013;
Grijalva et al, 2014); however, our data fine-tune the role of Hippo
during the early hypertrophic and proliferative phases of the regen-
erative response. Phosphorylated MST1 and LATS1 were detected in
quiescent livers; however, their phosphorylation increased at early
time points after PH. Although this may appear contradictory to a
proliferative response, this increase occurs during the hypertrophy
phase of regeneration before the onset of hepatocyte proliferation
(Miyaoka et al, 2012). As the hypertrophy phase transitions into the
proliferative phase, levels of p-MST and p-LATS1 decrease coincid-
ing with Ki67 immunostaining and YAP1 activation. We did not
observe phosphorylated MST1 or LATS1 following PH to be reduced
below their steady state levels, allowing us to speculate as to the
importance of the flux of their expression in the control of YAP1.
Moreover, one can speculate that the steady state levels of pMST
and pLATS needed to maintain YAP in a quiescent liver are not suf-
ficient to control its expression when the regenerative signals are
fully engaged, as occurring following PH. The increase of p-LATS1
coincided with the increase of its upstream regulator p-MST1, which
is supported by reports showing significant decrease of LATS1 phos-
phorylation following inactivation of MST1/2 (Lu et al, 2010).
However, it was also demonstrated that MST proteins could regulate
YAP1 independent of LATS1 (Zhou et al, 2009). Therefore, although
we observed a strong regulation of MST1 and LATS1 protein during
liver regeneration, we cannot conclude by which mechanism YAP1
is being controlled.
Several liver-specific knockout models targeting Hippo pathway
proteins such as MST1/2 (Zhou et al, 2009; Lu et al, 2010; Song
et al, 2010), NF2 (Benhamouche et al, 2010; Zhang et al, 2010) and
WW45 (Lee et al, 2010) have been generated. Notably, there is the
target-dependent effect in the liver. A liver-specific KO of MST1/2
resulted in hepatocyte proliferation, whereas NF2 depletion mainly
targeted biliary cells, and WW45 KO increased the number of
hepatic progenitor cells. As hepatocyte proliferation is fundamental
for liver regeneration, MST1/2 presents itself as an optimal thera-
peutic target. Moreover, compared to structural proteins, kinases
are easier targets for potential pharmacological intervention. Until
Figure 3. Hippo signaling and YAP activation are impaired in aged mice.
A Western blot detection of p-MST1, MST, p-YAP, YAP and TAZ in control and 40 h following PH in young and aged mice. TBP was used as a loading control.
Representative results from a single experiment with n = 6 independent animals. Each band is from an independent animal. Western blot quantification ratios are
graphically depicted. Protein levels were normalized to TBP and mean value of the group is plotted. Unpaired, two-tailed Student’s t-test was used to calculate the
significance between 0 h (resected liver) and 40 h following PH. Bars represent mean  SD.
B RT–PCR analysis of RNA isolated from mouse liver for Foxm1B, Birc5 and Ccnb1, Ccna2, Ccnd1 and Cdkn1A. RT–PCR data are presented as log2 fold change and each
value post-PH was calculated for each mouse by comparison with its resected liver lobe. Circle with red outline marks the aged non-regenerating livers as shown in
Fig 2B. Each dot is representing an independent animal.
Source data are available online for this figure.
Figure 4. Inhibition of MST provokes hepatocyte proliferation in vivo.
A Eight-week-old mice were injected with liposomes coupled to scrambled siRNA (siScr) or sequences targeting MST1 and MST2 (siMST). Each dot is representing an
independent animal. The amount (%) of Mst1 and Mst2 mRNA remaining in the liver was tested by RT–PCR 1, 3 and 6 days post-injection and calculated compared
to control non-transfected livers. Unpaired, two-tailed Student’s t-test was used to calculate the significance of mRNA remaining in comparison with non-transfected
control livers at each time point.
B Western blot detection of MST1, p-LATS1 and b-actin 1, 3 and 6 days post-siRNA injection. A representative animal from each time point is shown.
C Western blot detection of YAP1, p-YAP1, H3 and p-H3 3 days post-siRNA injection. Two representative animals from each group are shown. All samples were run on
the same blot. The blot is split due to non-consecutive loading of the samples.
D Quantitative RT–PCR analysis of RNA isolated from mouse liver for Foxm1B, Birc5 and Ccnb1, 1, 3 and 6 days post-injection. Log2 fold change was calculated using
non-transfected mouse liver as control. Unpaired two-tailed Student’s t-test was used to calculate the significance of fold change of in comparison with a panel of
non-transfected control livers.
E HNF4a and Ki67 were detected by IHC and cells positive for both were classified as proliferating hepatocytes. Ki67-positive hepatocytes are indicated with an asterisk
and Ki67-negative bile ducts/biliary cells with an arrow in tissue 3 days post-siRNA delivery. The percentages of positive hepatocytes at day 3 and day 6 post-injection
are graphed. Two-tailed Student’s t-test was used to calculate the significance of percentage of positive hepatocytes in comparison with non-transfected control
livers.
Data information: Throughout the figure, representative results from two independent experiments with n = 3 animals per group are depicted. Bars represent
mean  SD.
Source data are available online for this figure.
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now, no data are published on the effect of a liver-specific LATS1
and 2 deletion. Recently, however, a liver-specific Lats2 single-
knockout (Lats2flox/flox; Albumin-Cre, Lats2-cKO) was reported to
show no overt histological abnormalities nor developed liver
tumours up to 16 months of age (Park et al, 2016). MST1/2 regula-
tion of YAP1 is reported to be tissue specific, particularly in the liver
(Zhou et al, 2009). Thereby, kinases other than LATS may be
responsible for YAP1 phosphorylation downstream of MST1/2,
further supporting MST proteins as suitable targets.
We chose to use siRNAs as the means to genetically target
MST1/2. The temporary effect offered by siRNA is attractive in order
to minimize the chance that inhibition of Hippo signaling could
provoke liver overgrowth or hepatocyte transformation. Using
siRNA coupled with liposomes has the advantage of reaching our
target cell the hepatocyte with higher specificity, thereby reducing
the effect of YAP1 activation in other cell types. The liposomes used
in this study successfully reached the hepatocyte and delivered the
siRNA in a sufficient concentration to knock down our targeted
genes of interest. In young mice, this appeared to be achieved in the
absence of any additional stress/injury to the liver, as we did not
observe an increase of serum transaminase. Also, mice injected with
control siRNA to a scrambled sequence showed no significant signs
of proliferation. However, the poor recovery following PH of aged
animals receiving encapsulated control siRNA suggests that the liver
is stressed; however, this effect is most likely due to the liposome
delivery, as the siRNA targeting MST1/2 improved regeneration,
even compensating for the delivery system. Specific targeting of
MST1 or 2 should not result in liver injury as serum transaminases
are not elevated in MST1/2 double mutants (Lu et al, 2010).
Targeting MST1/2 with encapsulated liposomes reduced MST1/2
mRNA and MST1 protein, induced YAP1 activation and provoked
hepatocytes to re-enter cell cycle. YAP1 targets genes involved in
cell proliferation were increased, whereas CTGF was not increased
in mouse (Appendix Fig S3) or rat (Grijalva et al, 2014) liver follow-
ing PH. Targeting MST1/2 with siRNA did result in a mild pheno-
type, which may be viewed as a desired effect to avoid detrimental
side effects of inhibiting Hippo in the liver, or overexpressing YAP1
directly, such as hepatocyte overproliferation or de-differentiation
(Yimlamai et al, 2014). While our manuscript was under review, a
study reported siRNA nanoparticles targeting MST1, MST and Nf2
results in extensive proliferation of hepatocytes and activation of
YAP1 (Yin et al, 2016). In their model, hepatomegaly was only
observed in the triple knockdown, 15 days following repeated injec-
tions. This in part explains the mild phenotype we observed in
quiescent liver targeting only MST1 and MST2 after 6 days with a
single siRNA injection and advocates optimization of treatment
protocols. Nevertheless, both studies support the Hippo pathway as
a viable therapeutic target to manipulate liver growth.
By restoring regeneration in an aged mouse model, we were able
to demonstrate the potential clinical applicability of targeting the
Hippo pathway. Several groups have reported aged-related defects
in liver regeneration (Bucher et al, 1964; Fry et al, 1984; Wang
et al, 2002; Pibiri et al, 2015) and YAP1 activation was suggested to
help aged mice recover after PH (Pibiri et al, 2015). The beneficial
effect we observed with siMST could be a result of a direct activa-
tion of YAP1 in the targeted hepatocytes. Foxm1B expression is
restricted to proliferating cells and strongly up-regulated upon entry
into the S phase of cell cycle (Korver et al, 1997) and was increased
in liver injected with siMST. In a report by Wang et al, mice with
sustained hepatic Foxm1B overexpression were able to overcome
age-related defects during liver regeneration; however, Foxm1B
alone is insufficient to induce differentiated cells to enter cell cycle
(Ye et al, 1999; Wang et al, 2002). Birc5 and Ccnb1 were also
increased by MST1/2 RNAi. However, as MST1 is involved in other
signaling pathways including apoptotic signaling (Ardestani et al,
2014; Del Re et al, 2014; Chao et al, 2015), it is not conclusive
whether the effect we achieve is due only to YAP1 activation. This
question is prompted by our observations in the aged mice, in
which siMST-treated animals showed a survival advantage at 24 h
compared to the siScr control, a time point prior to the actual prolif-
erative phase of the regenerative response.
The Hippo pathway is becoming an attractive target in the liver
for therapeutic intervention in the field of hepatic malignancies
(Fitamant et al, 2015; Yimlamai et al, 2015) and hepatic re-growth
Figure 5. Inhibition of MST improves liver regeneration in aged mice.
A Aged mice (> 12 months) were injected i.v. with siScr or siMST. Twenty-four hours after siRNA injection, a 70% PH was performed and remnant/regenerating liver
tissue was harvested 40 h later. p.i. of the livers was calculated by IHC staining of Ki67-positive hepatocytes and livers were classified as () non-regenerating or (+)
regenerating based on the percentage of positive cells. Non-surviving animals were sacrificed before the 40-h end time point. “n” indicates the number of animals
per group.
B Ki67 immunostaining of the regenerating aged mice livers, 40 h post-PH. Sections were scanned using 3DHistech Pannoramic MIDI Scanner and quantitated with
Quant Center 2.0 software. p.i. values are provided on the image.
C Representative photomicrograph of an aged liver treated with siMST and stained with H&E and by IHC for CK19 and Ki67. Arrows indicate ductal regions with no
signs of reaction or oval cell expansion.
D Quantitative RT–PCR analysis of RNA isolated from mouse liver for Foxm1B, Birc5 and Ccnb1 at 0 and 40 h post-PH. Log2 fold change was calculated using non-
transfected/non-resected mouse liver as a control. Representative results from a single experiment with n = 6 animals per group are shown. Paired, two-tailed
Student’s t-test was used to calculate the significant change in signals between liver tissues at the time of resection (0 h) compared to 40 h post-PH.
E Percentage of Ki67-positive hepatocytes in aged and aged + siMST 40 h post-resection. Representative results from a single experiment with n = 6 independent aged
animals for group are shown. Two-tailed Student’s t-test was used to calculate the significance of percentage of positive hepatocytes of siMST-treated animals
compared to non-treated controls.
F Endpoint liver weight was taken of the remnant lobe and expressed as a percentage to total body weight. Representative results from a single experiment with n = 6
independent animals for group expect for control group where n = 6 are shown. Estimated liver-to-body weight ratio before PH in mice = 3.85  0.05 (SD). Unpaired,
two-tailed Student’s t-test was used to calculate the significance of each aged group in comparison with the control young group.
G Hepatocyte geometric diameter was determined (see Materials and Methods). Representative results from a single experiment with n = 3 independent animals per
group. Unpaired, two-tailed Student’s t-test was used to calculate the significant change in hepatocyte size in liver tissue with and without siMST 40 h post-PH.
Data information: Bars represent mean  SD. Scale bars, 50 lm.
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(Yin et al, 2016). As Hippo is also important for tissue stem cell
maintenance (Lu et al, 2010), these implications may reach beyond
the liver and to the repair and regeneration of other organs.
Research and development of small molecule kinase inhibitors that
modulate the activation of Hippo kinases or antisense drugs to
silence expression of key regulatory proteins hold promising thera-
peutic and investigative potential in regenerative medicine.
Materials and Methods
Partial hepatectomy model
The mice used in this study were 6- to 8-week- (~20 g) and
12-month-old (~29 g) female C57BL/6JRccHsd provided by Harlan,
the Netherlands. Animals were kept in a temperature-controlled
room with a 12-h dark/light cycle. Experiments were done with
Institutional Animal Care and Use Committee approval and in strict
accord with good animal practice as defined by the Office of Labora-
tory Animal Welfare. Littermates were randomly assigned to control
sham or partial hepatectomy groups. Mice were anesthetized by
isoflurane inhalation during an operation time of 15–20 min. For
analgesia, Temgesic (0.05 mg/kg) was injected i.p. prior to surgery.
Two-thirds partial hepatectomy (2/3 or 70%) was performed
according to methods previously described (Inderbitzin et al, 2006).
Briefly, following a laparotomy, vicryl 4.0 suture (VCP496, Ethicon)
was used to ligate and excise the median and left liver lobes. The
peritoneal cavity was washed with saline solution and the abdomen
was sutured closed. In sham-operated mice, a laparotomy was
performed, the liver was manipulated with a cotton-coated stick,
flushed with saline, and the abdomen was sutured closed. The
resected tissue was collected and used as a non-regenerating
matched control for each mouse. Liver tissue from non-operated
and sham-operated mice was also used as controls. Liver regenera-
tion was followed for various time points up to 6 days. At experi-
mental endpoints, mice were anesthetized by isoflurane inhalation.
Blood was collected via the vena cava and centrifuged for serum.
Mice were sacrificed by exsanguination. All excised tissues were cut
in 3 × 3 mm pieces, frozen in liquid nitrogen and stored at 80°C
or fixed in 4% formalin overnight at room temperature.
Primary liver cell isolations
Hepatocytes from control or regenerating livers were isolated using
a two-step enzymatic perfusion protocol (Portmann et al, 2013).
The viability of the isolated hepatocytes was determined by trypan
blue exclusion, and only preparations of over 90% viability were
used. The hepatocytes were seeded onto rat tail collagen-coated
tissue culture plastics in Dulbecco’s modified Eagle medium
containing 10% foetal bovine serum, left to attach for 1–2 h and
then washed twice with phosphate-buffered saline (PBS) to remove
unattached cells. The hepatocytes were cultured in arginine-free
Williams E medium supplemented with insulin (0.015 IU/ml),
hydrocortisone (5 lmol/l), penicillin (100 IU/ml), streptomycin
(100 lg/ml), glutamine (2 mmol/l) and ornithine (0.4 mmol/l) for
24 h before use.
Cholangiocytes were isolated by enzymatic tissue digestion, dif-
ferential density centrifugation followed by immunomagnetic
selection for CD326 (EpCAM). The cholangiocytes were cultured in
DMEM/F12 containing 5% foetal bovine serum, 10 ng/ml hepato-
cyte growth factor (HGF), 10 ng/ml epidermal growth factor (EGF),
4 lg/ml hydrocortisone, 10 ng/ml cholera toxin, 1.24 i.u./ml
insulin, 2 × 109M triiodothyronine and penicillin–streptomycin.
siRNA screen in BNL cells
BNL 1ME A.7R.1 (ATCC, TIB-75™) cells were cultured in DMEM
with 10% FBS, 100 U/ml penicillin and 100 lg/ml streptomycin
(Life Technology) in a humidified incubator at 37°C with 5% CO2.
All experiments were carried out at 60–70% confluence. Cells were
transfected with siRNA targeting MST1 (also known as STK3) ID:
s81598, s81597, s81599 and MST2 (also known as STK4) ID:
s211751, s211750, s211749 (Ambion, Life Technologies) using Lipo-
fectamine 2000 (Invitrogen) in DMEM with 10% FBS. After 48 h,
total proteins were extracted and analysed by Western blot.
siRNA LATS knockdown in HEPG2 cell line
HEPG2 cells were cultured in DMEM with 10% FBS, 100 U/ml peni-
cillin and 100 lg/ml streptomycin (Life Technology) in a humidified
incubator at 37°C with 5% CO2. All experiments were carried out at
60–70% confluence. Cells were transfected with siRNA targeting
LATS1 siGENOME Human LATS1 (9113) siRNA SMARTpool target-
ing four different sequences D-004632-01 (GAACCAAACUCUCAA
AACAA), D-004632-02 (GCAAGUCACUCUGCUAAUU), D-004632-03
(GAAAUCAAGUCGCUCAUGU) and D-004632-02 (GAUAAAGACAC
UAGGAAUA) (Dharmacon) using Lipofectamine 2000 (Invitrogen)
in DMEM with 10% FBS. After 72 h, total proteins were extracted
and analysed by Western blot.
Protein isolation and Western blot
Total protein extracts were isolated from liver tissue using 500 ll
RIPA lysis buffer and disassociated using a TissueLyser (Qiagen) for
2 min at 20 Hz. The liver lysates were centrifuged at 23,000 g for
15 min at 4°C, and supernatants were collected. To isolated
enriched nuclear protein extracts, liver tissue was crushed with
mortar and pestle while being kept frozen in liquid nitrogen and
further broken up with a manual homogenizer in cell lysis buffer
(10 mM Tris at pH 8.0, 150 mM NaCl, 1 mM EDTA and phos-
phatase inhibitors phenylmethylsulfonyl fluoride (PMSF), sodium
orthovanadate, sodium fluoride). Homogenates were centrifuged for
5 min at 3,200 g and the cytoplasmic fraction collected. Pellets were
re-suspended in nuclei extraction buffer (20 mM HEPES pH 7.9,
400 mM NaCl, 1 mM EDTA) and after 15 min on ice were centri-
fuged for 15 min at 15,000 g. All protein extraction buffers
contained protease inhibitor cocktail (P8340, Sigma). Protein
concentrations were determined with the Bio-Rad Protein Assay
System (Bio-Rad) as described by the manufacturer.
Equal amount of proteins were separated by SDS–PAGE and
transferred onto PVDF membrane (GE Healthcare, Amersham) by
wet transfer (Bio-Rad). Membranes were blocked in 5% not-fat dry
milk in TBST and incubated with primary antibodies overnight at
4°C and 90 min in the secondary antibody. All primary antibodies
were obtained from Cell Signaling unless otherwise noted: MST1
(1:500, #3682), MST2 (1:500, #3952), p-MST1/p-MST2 ((Thr183/
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Thr180) 1:500, #3681), LATS1 (1:500, #ab70561, Abcam), p-LATS1
((Ser909) 1:500, #9157), YAP1 (1:500, #4912), YAP/TAZ (1:1,000,
#8418), p-YAP1 ((Ser127) 1:1,000, #4911), H3 (1:2,000, #4499),
p-H3 ((Ser10) 1:2,000, #06-570, Upstate Biotechnology), HNF4a
(1:500, #SC-8987, Santa Cruz), CK-19 (1:2,000, #NB100-687, Novus
Biologicals) monoclonal anti-b-Actin–peroxidase clone AC-15
(1:50,000 #A3854, Sigma), TBP (1:1,000, #8515). Secondary anti-
body used was anti-rabbit-HRP (1:2,000–1:5,000) (Dako). Signals
were visualized by enhanced chemiluminescence (Western Light-
ning Plus ECL, Perkin Elmer) and films were developed with CURIX
60 (AGFA). The band size was estimated using Page Ruler™
Prestained Protein Ladder (Fermentas) and Precision Plus Protein™
DUAL Color Standards (BIO-RAD, #161-0374). Band densities were
analysed using ImageJ software and signals were normalized to TBP
or b-actin. The Student’s t-test was used for comparison of signal
intensities.
Immunohistochemistry
The tissue was processed for paraffin embedding. Paraffin sections
were cut at a thickness of 6 lm. Tissues were stained for histological
analysis with haematoxylin and eosin. Primary antibodies used were
HNF4a (SC-6556, Santa Cruz), YAP1 (#4912, Cell Signaling) and
Ki67 (clone SP6, RM-9106-R7 Thermo Scientific) followed by
secondary antibodies from Reactolab using Vectastain Elite ABC Kit
for goat IgG (PK-6105) or rabbit IgG (PK-6101). For quantification of
Ki67-positive hepatocytes in the knockdown experiment without PH,
20 high power fields were photographed per sample and hepatocytes
were manually counted for HNF4a- and Ki67-positive reactions. For
the quantification of the number of hepatocytes in proliferation in
aged and young mice, the 3DHISTECH Pannoramic MIDI Scanner
and 3DHISTECH Quant 2.0 software were used. A proliferation index
(p.i.) was calculated as a ratio of Ki67-positive nuclei to total number
of hepatocytes counted. The results are presented as the p.i.  SD
and were compared with an unpaired Student’s t-test.
Quantitative RT–PCR
Total RNA was isolated from all mouse samples and cells by using a
TRIzol reagent-based method following the manufacturer’s protocol
(Life Technologies). 500 ng of total RNA was used for cDNA synthe-
sis using Omniscript RT Kit 200 (Qiagen). mRNA was analysed by
quantitative RT–PCR with TaqMan gene expression assays and
reagents according to the standard protocols (Applied Biosystem).
Mouse probes used include amphiregulin (Mm01354339_m1), Birc5
(Mm00599749_m1), Cdkn1A (Mm004324480), CTGF (Mm011929
33_g1), Ccna2 (Mm00438063_m1), Ccnb1 (Mm01322 149_mH),
Ccnd1 (Mm00432359), Foxm1B (Mm00514925_m1), LATS1
(Mm01191886_m1), MST1 (Mm00451755_m1), MST2 (Mm
00490480_m1), TAZ (Mm00504978_m1), YAP1 (Mm01143263_m1),
18S (Mm02601777_g1) and TBP (Mm01277042_m1). Relative
changes in mRNA were calculated with the DDCt method. Ct values
of target genes (TG) were calculated relative to a reference gene
(RG; TBP or S18) using the following formula DCtTG ¼ CtTG  CtRG .
Experimental groups (exp) are normalized to control group (con) or
in the case of PH with matched resected tissue (res). DDCt ¼
DCtexp  DCtconorres. Fold change ¼ 2DDCt . Percentage (%) mRNA
remaining = 2DDCt  100.
siRNA–liposome preparation and femoral vein injection in
C57BL/6 mice
The siRNA sequences MST1 (50–30 sense GAGUGUCAAUAUUGC-
GAGAtt), MST2 (50–30 sense CAAGAGUCAUGAAAAUUGUtt), FVII
(Invivofectamine 2.0 kit) and in vivo siRNA negative control (Cat
# 4457287) and FVII siRNA (Cat # 4459408) were obtained from
Ambion Life Technologies. Invivofectamine 2.0 Reagent (Invitro-
gen) was used for the lipid-based in vivo RNAi delivery and
siRNA–liposome complexes were prepared according the manufac-
turer’s protocol. Briefly, siRNAs were diluted in DNase, RNase free
water to a final concentration of 4 mg/ml. The diluted oligos were
mixed 1:1 with the complexation buffer. Invivofectamine was
added 1:1 to the siRNA complexation buffer mixture followed by
10-min incubation at room temperature. siRNA–liposome
complexes were prepared for injection by dialysis (SPECTRA/Pro).
The injected concentration of MST1, MST2 and siRNA negative
control siRNA was 1 mg/ml, whereas FVII concentration was
0.3 mg/ml. For in vivo delivery, mice were anesthetized by isoflu-
rane inhalation, the femoral vein of the internal side of the hind
leg was exposed, and siRNA–liposome complexes were injected
10 ll/g mouse with a 29 G × ½ in needle. After injection, the skin
was sutured.
Genomic microarray
Genomic microarray was performed via the Genomic Platform,
University of Geneva. The raw microarray data were background-
corrected, normalized using the RMA method as implemented in the
R/Bioconductor package affy (Gautier et al, 2004). Probe sets were
redefined using the alternative chip definition file mogene20stm-
mentrezgcdf, as described by Dai et al (2005). Differential gene
expression was calculated using the moderated t-test as described
by Ritchie et al (2015) and implemented in the R/Bioconductor
package limma.
Pathway analysis
The output of limma was used to perform GSEA using the SetRank
method (C. Simillion, R. Liechti, H. Lischer, V. Ioannidis & R.
Bruggman, submitted). The key principle of this algorithm is that it
discards gene sets that have initially been flagged as significant, if
their significance is only due to the overlap with another gene set. It
calculates the P-value of a gene set using the ranking of its genes in
the ordered list of P-values as calculated by limma. The following
databases were searched for significant gene sets: BIOCYC (Karp
et al, 2005), Gene Ontology (Ashburner et al, 2000), ITFP (Zheng
et al, 2008), KEGG (Kanehisa et al, 2014), LIPID MAPS (Fahy et al,
2009), PhosphoSitePlus (Hornbeck et al, 2012), REACTOME (Croft
et al, 2014) and WikiPathways (Kelder et al, 2012).
Measurement of hepatocyte dimensions
The method was adapted from Chen et al (2005). Formalin-fixed
liver sections were stained for the membrane proteins claudin-3
(Novus Biologicals, Cat. NBP1-35668) and b-catenin (Sigma, Cat.
C7082) and visualized by immunofluorescence. Images were
acquired with an inverted confocal microscope (Zeiss LSM710).
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The scale was set for each image using the set scale option of
ImageJ software. The perpendicular dimensions of cell width and
length were annotated by hand using the line tool option. The
cell diameter was calculated as the mean of all measured perpen-
dicular dimensions. Four images from randomly selected regions
were taken per animal and > 250 measurements were taken per
region.
Measurement of liver injury
Serum samples post-PH or post-injection with siScr or siMST
were collected to assess extent of liver injury using assays to
measure ALT and AST (P800; Modular Analytics EVO, Roche,
Germany).
Statistics
The graphs and the statistics used in this study have been made by
using GraphPad Prism software. P-values were calculated using an
unpaired, two-tailed Student’s t-test for all images, except Fig 5C
that used a paired, two-tailed Student’s t-test.
Expanded View for this article is available online.
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